NONOF Quote, Financials, Valuation and Earnings

Galecto has a net margin of 38.28% compared to Novo Nordisk AS's net margin of --. Novo Nordisk AS's return on equity of 88.95% beat Galecto's return on equity of --.

Novo Nordisk AS has a consensus price target of --, signalling upside risk potential of 8.35%. On the other hand Galecto has an analysts' consensus of -- which suggests that it could grow by 111.83%. Given that Galecto has higher upside potential than Novo Nordisk AS, analysts believe Galecto is more attractive than Novo Nordisk AS.

Novo Nordisk AS has a beta of 0.464, which suggesting that the stock is 53.63% less volatile than S&P 500. In comparison Galecto has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Novo Nordisk AS has a quarterly dividend of $0.52 per share corresponding to a yield of 1.65%. Galecto offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 37.96% of its earnings as a dividend. Galecto pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk AS quarterly revenues are $10.5B, which are larger than Galecto quarterly revenues of --. Novo Nordisk AS's net income of $4B is higher than Galecto's net income of -$3.9M. Notably, Novo Nordisk AS's price-to-earnings ratio is 28.47x while Galecto's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 9.97x versus -- for Galecto. Usually stocks with elevated PS ratios are considered overvalued.

Genmab AS has a net margin of 38.28% compared to Novo Nordisk AS's net margin of 22.85%. Novo Nordisk AS's return on equity of 88.95% beat Genmab AS's return on equity of 14.86%.

Novo Nordisk AS has a consensus price target of --, signalling upside risk potential of 8.35%. On the other hand Genmab AS has an analysts' consensus of $36.56 which suggests that it could grow by 76.09%. Given that Genmab AS has higher upside potential than Novo Nordisk AS, analysts believe Genmab AS is more attractive than Novo Nordisk AS.

Novo Nordisk AS has a beta of 0.464, which suggesting that the stock is 53.63% less volatile than S&P 500. In comparison Genmab AS has a beta of 0.960, suggesting its less volatile than the S&P 500 by 3.991%.

Novo Nordisk AS has a quarterly dividend of $0.52 per share corresponding to a yield of 1.65%. Genmab AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 37.96% of its earnings as a dividend. Genmab AS pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk AS quarterly revenues are $10.5B, which are larger than Genmab AS quarterly revenues of $816.4M. Novo Nordisk AS's net income of $4B is higher than Genmab AS's net income of $186.6M. Notably, Novo Nordisk AS's price-to-earnings ratio is 28.47x while Genmab AS's PE ratio is 19.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 9.97x versus 4.68x for Genmab AS. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 38.28% compared to Novo Nordisk AS's net margin of 8.48%. Novo Nordisk AS's return on equity of 88.95% beat Eli Lilly and's return on equity of 66.4%.

Novo Nordisk AS has a consensus price target of --, signalling upside risk potential of 8.35%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 23.58%. Given that Eli Lilly and has higher upside potential than Novo Nordisk AS, analysts believe Eli Lilly and is more attractive than Novo Nordisk AS.

Novo Nordisk AS has a beta of 0.464, which suggesting that the stock is 53.63% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.409, suggesting its less volatile than the S&P 500 by 59.07%.

Novo Nordisk AS has a quarterly dividend of $0.52 per share corresponding to a yield of 1.65%. Eli Lilly and offers a yield of 0.65% to investors and pays a quarterly dividend of $1.30 per share. Novo Nordisk AS pays 37.96% of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk AS quarterly revenues are $10.5B, which are smaller than Eli Lilly and quarterly revenues of $11.4B. Novo Nordisk AS's net income of $4B is higher than Eli Lilly and's net income of $970.3M. Notably, Novo Nordisk AS's price-to-earnings ratio is 28.47x while Eli Lilly and's PE ratio is 86.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 9.97x versus 17.62x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.